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translational research of many disease areas requires a longitudinal understanding of disease 
development and progression across all biologically relevant scales. Several corresponding studies 
are now available. However, to compile a comprehensive picture of a specific disease, multiple studies 
need to be analyzed and compared. A large number of clinical studies is nowadays conducted in the 
context of drug development in pharmaceutical research. However, legal and ethical constraints 
typically do not allow for sharing sensitive patient data. in consequence there exist data “silos”, 
which slow down the overall scientific progress in translational research. In this paper, we suggest 
the idea of a virtual cohort (Vc) to address this limitation. our key idea is to describe a longitudinal 
patient cohort with the help of a generative statistical model, namely a modular Bayesian network, 
in which individual modules are represented as sparse autoencoder networks. We show that with 
the help of such a model we can simulate subjects that are highly similar to real ones. our approach 
allows for incorporating arbitrary multi-scale, multi-modal data without making specific distribution 
assumptions. Moreover, we demonstrate the possibility to simulate interventions (e.g. via a 
treatment) in the VC. Overall, our proposed approach opens the possibility to build sufficiently realistic 
Vcs for multiple disease areas in the future.
Translational research of many disease areas requires a longitudinal understanding of disease development and 
progression across all biologically relevant scales. Examples of corresponding observational clinical studies 
include the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (https ://adni.loni.usc.edu/) (omics, neuro-
imaging, longitudinal clinical data), the Parkinson’s Progression Markers Initiative (PPMI) (https ://www.ppmi-
info.org/) (omics, neuro-imaging, longitudinal clinical data), the All-of-us cohort (https ://allof us.nih.gov/) 
(omics, behavioral, electronic medical records, environmental data) and the GENIE project (https ://www.aacr.
org/Resea rch/Resea rch/Pages /aacr-proje ct-genie .asp) (genomic and longitudinal real-world clinical data). These 
studies provide unique opportunities to obtain an increasingly holistic view of a patient’s health trajectory and 
allow e.g. for developing models of disease  risk1,2, disease  progression3-6 or different disease  stages7.
Each of these studies has unavoidably certain biases due to inclusion/exclusion criteria or over-representation 
of specific geographic regions and ethnicities. Moreover, usually neither the same clinical outcome measures 
nor the same molecular data are systematically collected in different studies of the same disease. Accordingly, 
compilation of a comprehensive view of a specific disease requires to analyze and compare multiple studies. A 
large number of clinical studies is nowadays conducted in the context of drug development in pharmaceutical 
open
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research. However, legal and ethical constraints typically do not allow for sharing sensitive patient data outside 
the organization that is responsible for the study. Even within one and the same organization the same reasons 
sometimes prevent data sharing. In consequence there exist data “silos”, which slow down the overall scientific 
progress in translational research.
In this paper, we suggest the idea of a virtual cohort (VC) to address this limitation. Our idea is to describe a 
longitudinal patient cohort with the help of a statistical model (namely a Bayesian Network) in conjunction with 
deep learning techniques (sparse autoencoders). This allows for simulating subjects that are sufficiently similar 
to real ones and can be shared with other organizations. Researchers could then develop models and generate 
hypotheses based on VCs that can later on be tested with the help of real data within their own organization. 
Hence, we overcome the aforementioned data privacy issues regarding sharing of real patient data. Moreover, 
we demonstrate that VCs open the opportunity to simulate scenarios, which have not been observed in reality 
(e.g. a certain shift towards a more healthy population). Our work should at this point be discriminated from 
existing work on virtual trial simulation, which mostly focuses on pharmacokinetic-pharmacodynamic (PKPD) 
modeling in clinical study design and typically involves mechanistic modeling of well understood biological 
 processes8. In contrast, the idea behind our VC concept is to cover the complex interplay of different biological 
scales and data modalities (clinical, genomic, imaging, etc.) within one modeling framework. This allows for 
generating virtual patient trajectories that are highly similar to real ones with respect to relevant characteristics. 
We consider Bayesian Networks (BNs) as interesting candidates for realizing this ambition, because they allow 
for integrating highly heterogeneous data within one modeling  framework9 while allowing to address one of the 
main challenging aspects of clinical study data, namely high numbers of missing values. Moreover, BNs belong to 
the family of generative models and hence can be used to simulate virtual patient trajectories after model  fitting10.
From a methodological point of view one of the main challenging issues that we address in this paper is that 
many patients typically drop out of a study at some point, e.g. due to symptom worsening. Most authors thus 
focused their modeling efforts only on patients that were observed till the end of a  study3, which can result into 
drastic loss of data and potential model biases. One of the important aspects of our proposed approach is there-
fore a mechanism, which directly incorporates systematic missingness of data in a longitudinal patient study 
into a BN model. A further distinction point of our work is the combination with deep learning techniques, 
specifically autoencoder networks, to reduce the dimensionality of our data. It further enables the application 
of BN structure learning to data of realistic sample size at reasonable computational cost. Our approach can 
be interpreted as a special type of Module  Network11, which allows for incorporating arbitrary multi-scale, 
multi-modal data without making specific distribution assumptions. We suggest a conservative approach to 
simulate virtual patients, which allows for scoring virtual subjects compared to the distribution of real patients 
and potentially rejecting them, if they might be considered as outliers. Using this approach we demonstrate that 
our simulated Alzheimer’s (AD) and Parkinson’s Disease (PD) VCs cannot be reliably discriminated from real 
patients in ADNI and PPMI. Furthermore, our method can be used to simulate a VC for a situation that has not 
been observed in the real data, e.g. a less cognitively impaired AD cohort.
Results
Used datasets. ADNI. Data were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
database (adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private partnership, led by Principal 
Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic reso-
nance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neu-
ropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) 
and early Alzheimer’s disease (AD). For up-to-date information, see www.adni-info.org.
The study includes 417 cognitively normal patients, 106 subjects with significant memory concern, 310 
subjects with early mild cognitive impairment, 562 subjects with late mild cognitive impairment and further 
342 subjects, which were diagnosed with AD at the beginning of the study. In this work, we used longitudi-
nal data from 689 patients that were initially either diagnosed as AD (n = 342) or converted into AD patients 
during the study. ADNI data includes single-nucleotide polymorphism (SNP) based genotype, APOE4 status, 
CSF (cerebrospinal fluid) biomarkers, volume measurements of seven brain regions as well as different clinical 
and neuropsychological test results. In addition to the 7 brain volume measurements provided in the original 
ADNIMERGE dataset, we calculated 68 cortical brain region volumes from raw images using Desikan parcella-
tion (details in “Methods” section). Out of more than 300,000 SNPs that have been commonly measured in the 
ADNI1 and ADNI2/GO phases of the ADNI study we focused on 110, which have previously been implicated 
as relevant in the transition of a normal/cognitively impaired state to  AD2. We grouped all features measured in 
ADNI into brain volumes, cortical brain regions, cognition tests, CSF markers, genotype (SNPs + APOE4 status), 
demographic features and baseline diagnosis (see exact definitions in Supplements). We generally discarded 
features with more than 50% missing values, which reduced the number of visits modeled by our approach to 
baseline, month 6, month 12 and month 24.
PPMI. Data were obtained from the Parkinson’s Progression Markers Initiative (PPMI) database (www.ppmi-
info.org/data). For up-to-date information on the study, visit www.ppmi-info.org. PPMI consists of multiple 
cohorts from a network of clinical sites with the aim to identify and verify progression markers in PD. It is a 
multi-modal, longitudinal observation study with data collected using standardized  protocols12. PPMI com-
prises of eight cohorts with different clinical and genetic characteristics.
Here we used data of 362 de novo PD patient cohort. These untreated subjects were diagnosed with PD for 
2 years or less and showed signs of resting tremor, bradykinesia, and rigidity during the last 2 years. The dataset 
contains 831 clinical variables, which we categorized into 12 groups, such as patient demographics, patient PD 
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history, imaging, non-motor symptoms, CSF markers and UPDRS (see complete list and exact definition in 
Supplements). PPMI assesses clinical variables at baseline and 11 follow-up visits. Noteworthy, some variables 
were assessed irregularly and not for all patients, yielding missing values. We generally discarded features with 
more than 50% missing values for modeling purposes. Accordingly, there were 12 time points included into our 
model, but not all variables were available at each time point (see Supplements).
Motivation and overview about developed method. In a naive way one might consider simulating 
a VC by assuming all variables in a clinical cohort to follow a Gaussian distribution and inferring population 
parameters from reported summary statistics (means, standard deviations) as parameters. However, the Gauss-
ian distribution assumption does not hold true in many cases, e.g. for categorical variables. A further big disad-
vantage is the ignorance of statistical dependencies between variables. For example, sampling age and height of 
persons independently could result into a virtual subject that is 6 months old and has a height of 1.80 m.
BNs explicitly describe conditional statistical dependencies between variables and thus address this issue. 
Moreover, they are generative models, i.e. represent a statistical distribution, from which data can then be drawn. 
However, in reality the true BN structure is only partially known. Learning the network structure from data 
is in principle possible, but computationally NP  hard28. The number of possible network structures between n 
variables grows super-exponentially with n, which raises severe concerns regarding the identifiability of the true 
edges from limited number of patients in clinical studies. Moreover, the limited number of patients can yield 
overfitting of parameters of the BN.
To address these concerns we here developed a combined deep learning and BN based approach to simulate 
longitudinal multi-modal, multi-scale VCs. Our approach, summarized in Fig. 1, starts with the definition of vari-
able groups and potentially allowed dependencies between these groups (Figures S1, S2). This step significantly 
reduces the number of parameters and possible BN structures. Moreover, we model missing values (specifically 
including those that cannot be regarded as missing by randomness). To aggregate data on the level of variable 
groups we use sparse autoencoders, which do not make any assumptions about the underlying statistical distribu-
tion. Next we discretize the data to enable efficient BN structure and parameter learning for arbitrary statistical 
distributions and non-linear dependencies between variable groups. The fully parametrized BN is then used to 
draw virtual subjects. Further details about our approach, including the relationship to existing BN methods, 
are described in the “Methods” section of this paper.
A question that is critical for the utility of a VC is, in how far simulated data statistically resembles real 
subjects. The definition of a quality criterion for VCs is difficult, and there is probably not a unique answer. In 
this work we propose a conservative approach, in which we iteratively train a weighted Random Forest (RF) 
 classifier13 that allows us to score and potentially also to reject virtual subjects. Our method is described in detail 
in the “Methods” section of this paper.
Virtual AD and pD patients look realistic. To validate our VC generation scheme we generated the 
same number of virtual as well as real patients for ADNI and PPMI and then asked whether a conventional RF 
classifier was able to separate between virtual and real subjects within a 10 times repeated 10-fold cross-valida-
tion scheme. That means we sequentially left out 1/10 of subjects and trained a RF on the remaining subjects to 
learn the discrimination between real and virtual subjects. We used the left out portion of the data to assess the 
prediction performance of the RF. We used the partial area under ROC curve (pAUC) at a pre-specified true 
Figure 1.  Overview about our modeling approach for longitudinal patient cohorts: (A) Approach to 
estimate BN, including dimensionality reduction via sparse autoencoders and modeling of missing data. (B) 
Conservative approach to simulate virtual patients.
4Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:10971  | https://doi.org/10.1038/s41598-020-67398-4
www.nature.com/scientificreports/
positive rate of 90% for real patients as a measure of the prediction performance. That means we looked at the 
area under the ROC curve at which the detection rate for real patient was between 90% and 100%. This was done 
to account for the fact that misclassification of a virtual patient as real would be far less relevant as the other way 
around. Following the implementation in R-package  pROC14 the pAUC is a measure in the interval [0, 1], where 
0.5 represents chance level.
We compared our proposed conservative simulation approach to drawing virtual patients directly from 
the BN model fitted to the entire data. Figures S7 and S8 indicate a clear benefit of our proposed method as 
the pAUC value is lower for the conservative approach compared to directly drawing virtual subjects from the 
Bayesian Network.
Figure 2 demonstrates that for both, ADNI and PPMI, the cross-validated classification performance to 
detect virtual patients is not clearly better than chance level. This situation did also not change significantly when 
generating a varying number of more virtual than real patients (Figs. 3, 4).
In addition to the RF based multivariate evaluation we inspected, marginal variable distributions (Figures S9, 
S10). We assessed separately for each variable via a χ2-test whether the null hypothesis of virtual and real patient 
samples coming from the same statistical distribution could be rejected (homogeneity test). Results shown in 
Tables S3, S5 demonstrate that after multiple testing correction univariate differences between virtual and real 
patient samples were in the vast majority of cases insignificant, which is in agreement to the findings from our 
RF based evaluation. Note that statistical significance in general is dependent on sample size and always has to 
be interpreted together with effect size. Thus, we think that our suggested RF based evaluation constitutes a more 
direct and interpretable way to assess the quality of a VC. At this point we should mention that our suggested RF 
method assigns to each virtual patient a confidence score, namely the probability to belong to the class of real 
patients. Figures 5 and 6 visualize these confidence scores with a color code in a multiple correspondence analysis 
plot (a technique similar to PCA that is devoted to discrete  data15). Altogether, we conclude that our proposed 
approach results into VC simulations that exhibit a sufficient degree of similarity to real patients.
Our suggested approach relies on an initial data discretization step followed by BN learning and VC simula-
tion. We compared the VC generated by this approach to an alternative one, in which the data discretization 
was omitted and instead a hybrid continuous/discrete BN was directly learned from the data (details in “Meth-
ods” section). As demonstrated by Figure S11 this approach was clearly inferior to our suggested one, because 
it resulted in a significantly better discrimination of virtual from real patients. This was likely due to the false 
assumption made by the hybrid BN that all continuous features would follow a Gaussian distribution. Hence, 
hybrid BNs were not considered further during the rest of this paper, and all presented results refer to our sug-
gested method.
Bayesian network structures reflect expected causal associations. To gain a better understanding 
of the variable dependencies learned by our BN models we performed a non-parametric  bootstrap16. That means 
we sampled for 1,000 times n patients (with n being the number of patients in each dataset) with replacement, 
and for each of these 1,000 bootstrap samples we learned a complete Bayesian Network structure. We then 
counted the relative frequency of observing a particular edge. Figure 7 depicts the network structure for ADNI 
Figure 2.  Performance of a random forest to correctly identify virtual subjects, measured via the partial area 
under ROC curve (pAUC) at a pre-specified detection rate of ≥90% for real patients. The pAUC was assessed on 
test sets within 10 repeats of a tenfold cross-validation procedure. Accordingly, boxplots show the distribution of 
the tenfold cross-validated pAUC that was obtained from 10 repeats of the cross-validation procedure.
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and Figure S6 depict the structure learned by PPMI data. The description of individual variables is illustrated in 
Table S3 and Table S5.
As expected, edges connecting variables, which represent the same group of features (e.g. UPDRS, CSF 
biomarkers, brain volume measurements) at different visits were inferred more stable than edges between dif-
ferent variable groups. That means BN structure learning was able to stable learn longitudinal dependencies in 
the data. This is e.g. marked by the connections between variables DX.BL (baseline diagnosis), DX.6 (diagnosis 
at 6 months), DX.12 (diagnosis at 12 months) and DX.24 (diagnosis at 24 months) in ADNI. Clinical diagnoses 
at each time point is dependent on cognitive impairment scores at the same time point, because the clinical 
diagnosis of dementia in practice is done on the basis of such tests.
In addition, in ADNI stable connections between genotype (SNPs) and baseline diagnosis, cognitive impair-
ment scores (Cog.bl) and amyloid PET scan diagnostics (FDG) were found. We investigated the relative influ-
ence of individual SNPs in the sparse autoencoder network output to understand these connections better. This 
was done via the random input permutation method described in Gedeon et al.17, see “Methods” section for 
more details. Altogether there was a non-zero influence of all 110 SNPs plus APOE4 status in the SNP group 
(see Supplementary Excel file). The most relevant SNP (rs9384488) has been associated with quantitative global 
cortical amyloid-β  load18. Amyloid-β plaques are one of the hallmarks of Alzheimer’s Disease, and amyloid-β 
measurements are part of the CSF variable group, hence providing an interpretation of the SNP → CSF edge in 
our BN as well as SNP → FDG.
In PPMI the edge of UPDRS1 to non-motor symptoms reflects (found in about 500/1000 BN reconstructions) 
the fact that the UPDRS scoring system comprises three parts, and the first part captures non-motor symptoms 
(cognitive function, behavior and mood)19. Similarly, the stable edge between non-motor symptoms and RBD 
(REM Sleep Behavior disorder score) can be explained by the fact that sleeping disorder assessment is part of 
non-motor symptom related variables in PPMI.
In summary, BN structures learned by our models reflected expected variable dependencies in both datasets.
Figure 3.  Performance of random forest classifier to correctly identify a given number of real ADNI patients 
among virtual subjects. The performance was measured via the partial area under ROC scurve (pAUC) at a 
pre-specified detection rate of ±90% for real patients. The pAUC was assessed on test sets within 10 repeats of 
a tenfold cross-validation procedure. Accordingly, boxplots show the distribution of the tenfold cross-validated 
pAUC that was obtained from 10 repeats of the cross-validation procedure.
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Simulating an intervention in a Vc. As pointed out before the final BN structure learned from ADNI 
represents expected dependencies between variable groups and indeed all of these dependencies can be regarded 
as causal (Fig.  7, solid edges): In particular note that the effect of genotype (SNPs) on cognitive assessment 
scores (Cog.bl), amyloid PET scan diagnostics (FDG.bl) and baseline diagnosis can only be interpreted causally. 
Likewise, the influence of gender on subcortical brain volumes can only be interpreted causally, although there 
potentially exist mediators such as longevity (women on average live longer than men).
To further exemplify the use of our causal BN, we simulated an intervention for dementia and Mild Cog-
nitively Impaired (MCI) patients at baseline that shifted their cognition scores (ADAS11, ADAS13, MMSE, 
CDRSB, FAQ, RAVLT) towards the median score of the cognitively normal patients (n = 423), e.g. via a drug. 
Dementia is the most severe stage in AD patients and MCI is the stage between cognitively normal decline and 
dementia decline. We encoded perturbed cognition scores via the autoencoder model that we had trained earlier 
on cognition scores of real patients. We then simulated the same number of virtual subject trajectories as real 
patients while conditioning on the shift in study baseline cognitive assessment scores. That means we used the 
perturbed cognition scores of real patients and then sequentially drew data for each dependent variable using 
the conditional probability tables (i.e. BN parameters) learned by our model. This implies that the intervened 
node becomes statistically independent from its parents, i.e. all incoming edges of variable Cog.bl are deleted 
in the intervened  network20.
Figure 8 demonstrates, how the effect of our counter-factual improvement of cognition scores at base-
line resulted into an expected significant shift of diagnoses towards “cognitively normal” or “mild cognitively 
impaired” throughout the study. Hence, our simulation of a “perturbed” ADNI cohort underlines the validity 
of our BN model.
Altogether this example underlines the validity of our BN models and demonstrate the possibility to—at least 
qualitatively—study intervention effects in silico.
Figure 4.  Performance of Random Forest Classifier To correctly identify a given number of real PPMI patients 
among virtual subjects. The performance was via the partial area under ROCcurve (pAUC) at a pre-specified 
detection rate of ≥90% for real patients. The pAUC was assessed on test sets within 10 repeats of a tenfold cross-
validation procedure. Accordingly, boxplots show the distribution of the tenfold cross-validated pAUC that was 
obtained from 10 repeats of the cross-validation procedure.
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Figure 5.  Multiple correspondence analysis plot of real ADNI and virtual patients. The probability of a virtual 
patient to belong to the real data is shown via a color code.
Figure 6.  Multiple correspondence analysis plot of real PPMI and virtual patients. The probability of a virtual 
patient to belong to the real data is shown via a color code.
8Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:10971  | https://doi.org/10.1038/s41598-020-67398-4
www.nature.com/scientificreports/
Figure 7.  Variable dependencies identified in ADNI dataset in more than 100/1,000 bootstrapped Bayesian 
network reconstructions (dashed lines; relative frequency = edge label). Solid edges indicate variable 
dependencies that are found commonly in bootstrapped Bayesian Network reconstruction and the final 
Bayesian Network topology.
Figure 8.  Simulation of a VC with an intervention: The figure shows diagnostic labels of 689 real ADNI patients 
(red) and of a simulated cohort of the same size (blue) at different visits. The cognitive assessment scores of 
the simulated cohort have been shifted at baseline. MCI, mild cognitive impairment; NL, cognitively normal; 
unknown, unknown diagnosis/diagnosis not reported.
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Discussion
To our knowledge this paper demonstrates for the first time a realistic simulation of virtual clinical subject tra-
jectories across multiple biological scales and data modalities outside the area of mechanistically well understood 
biological processes. This was achieved via a combination of deep learning techniques (sparse autoencoders) 
to significantly reduce the input dimensionality of our data and BN learning. The BN allows us to model miss-
ing data (specifically MNAR) and serves as a generative model, from which patient trajectories can be drawn. 
We proposed a conservative approach to simulate VCs, which allows to score and reject virtual subjects, if 
they appear different from real ones. Using this method we showed that virtual and real patient trajectories are 
highly similar, but not identical. Hence, our proposed approach opens the possibility to build virtual and at the 
same time realistic versions of clinical studies across multiple disease areas in the future. These virtual studies 
could then be shared with the larger research community, even, if the raw data cannot because of legal or ethical 
constraints. Hence, our method could help to unlock one of the key bottlenecks in biomedical research in data 
scarce disease areas.
We also showed that our VC approach allows for simulating interventions and studying their downstream 
effects in a qualitative manner in silico. Such an approach could help the design of future clinical studies, because 
it allows to assess, which variables or variables groups are more likely to show differences after a planned inter-
vention (e.g. with a drug).
Our proposed approach is not without limitations: Modular BN structure learning requires to define variable 
groups and constraints on the network structure, which implies a detailed understanding of the data. Moreover, 
we typically need to discretize input data to account for non-linearities between input variables while making 
BN structure and parameter learning at the same time computationally efficient. BN structure and parameter 
learning requires sufficiently large datasets that are representative for the disease population. In addition, our 
method uses a sparse autoencoder based aggregation of input features into variable groups, which naturally 
implies computational costs and a certain loss of information. Drawings of virtual patients from the modular 
BN model thus make the re-identification of real patients from the training data relatively unlikely. However, in 
its current implementation our approach does not provide strict theoretical guarantees for this situation. But, we 
like to point out that privacy preserving training of neural network models is possible in  principle21. Training all 
sparse autoencoders via the modified stochastic gradient descent algorithm proposed by Abadi et al. provides 
theoretical guarantees on data privacy of our entire modular BN model. In future work we will explore this 
aspect further and make an according implementation available. Altogether, the work presented here can only 
be seen as a first proof of concept for the idea of simulating realistic multi-scale, multi-modal VCs, and further 
methodological advancements are necessary.
Methods
Bayesian networks for non‑stationary mixed static and longitudinal data. The key ingredient 
of our proposed approach is a Bayesian Network (BN) describing longitudinal patient trajectories in a multi-
modal, multi-scale manner: Let G = (V, E) be a directed acyclic graph (DAG) and X = (Xv)v ∊ V a set of random 
variables indexed by nodes in V. X is called a Bayesian network with respect to G, if the joint distribution p(X1, 
X2, ..., Xn) factorizes according to:
where pa(v) denotes the parents of node v and xpa(v) their joint  configuration10. For a given node v we sum-
marize the set of associated conditional probabilities into a parameter vector θv, and these parameter vectors are 
assumed to be statistically independent for different nodes v, v′.
In our situation there exists a subset X˜ ⊂ X  such that measurements are time dependent, i.e. 
x˜ = (x˜(1)), . . . , x˜(T)) with T being the number of visits. Dynamic Bayesian  Networks22 usually deal with thiss 
situation by implicitly unfolding the BN structure over time, i.e. introducing for each visit t a separate copy X˜(t) 
of X˜ while requiring that edges always point from time slice t to time slice t + 1 (corresponding to a first order 
Markov process). This implicit unfolding assumes a stationary Markov process, i.e. parameters θ do not change 
with time. In our setting this assumption is most likely wrong, because patients change in their disease outcome 
during the course of a study, i.e. p(X˜(t)|X˜(t − 1)) �= p(X˜(t + 1)|X˜(t)) . Hence, we here use an unfolding strategy, 
in which we explicitly use different copies X˜ (t) for each time point.
Dealing with missing data. One of the key challenges with longitudinal patient data is missing values, 
which can result due to different reasons: (a) patients drop out of a study, e.g. due to worsening of symptoms; (b) 
a certain diagnostic test is not taken at a particular visit (e.g. due to lack of patient agreement), potentially result-
ing into missing information for entire variable groups; (c) unclear further reasons, time constraints, data quality 
issues, etc. From a statistical point of view these reasons manifest into different mechanisms of missing  data23,24:
1. missing completely at random (MCAR) The probability of missing information is not related to either the 
specific value which is supposed to be obtained or other observed data. Hence, entire patient records could 
be skipped without introducing any bias. However, this type of missing data mechanism is probably rare in 
clinical studies.
2. missing at random (MAR) The probability of missing information depends on other observed data, but is not 
related to the specific missing value which is expected to be obtained. An example would be patient drop out 
due to the worsening of certain symptoms, which are at the same time recorded during the study.
p(X1 = x1, X2 = x2, . . . , Xn = xn) =
∏
v∈V
p(Xv = xv|Xpa(v) = xpa(v))
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3. missing not at random (MNAR) any reason for missing data, which is neither MCAR or MAR. MNAR is 
problematic, because the only way to obtain unbiased estimates is to model missing data.
Missing values in ADNI and PPMI data are most likely a combination of MAR and MNAR mechanisms. In gen-
eral, multiple imputation methods have been proposed to deal with missing data in longitudinal patient  data24. 
Specifically for MNAR it has been suggested to explicitly encode systematic missingness of variables or variable 
groups via dedicated indicator  variables25. In our BN framework these auxiliary variables are fixed parents of all 
nodes, which contain missing values in a “systematic” way, and there are no further edges learned for auxiliary 
variables. We introduced one auxiliary variable for each variable group and visit to account for patient drop-out, 
i.e. MNAR. Moreover, in case of features that are assessed at different visits we enforced auxiliary variables to 
point from one to the next visit. For example, in ADNI dataset we introduced auxiliary variables for brain volume 
measurements at baseline, visit 6 months, visit 12 month, visit 24 month. Accordingly, the auxiliary variable for 
the feature “brain.bl” was also a parent of the auxiliary variable for the feature “brain.m06” (Figure S1). Details 
about the precise definition of auxiliary variables used in our work can be found in the Supplementary material.
A consequence of auxiliary variables is that they make parameter estimates conditionally dependent on 
the missingness information, hence accounting for potential biases of the multiple imputation (due to hidden 
confounding factors), which in our case was conducted via the missForest  method26. Briefly, missForest is a 
non-parametric multiple imputation approach for mixed data types, which uses Random Forests to iteratively 
predict missing values in each variable based on information in all other features. Starting from initial guesses 
of missing values, the method runs through several iterations of predictions until convergence of missing values 
can be observed. Stekhoven and Bühlmann demonstrated that specifically for mixed discrete/continuous data 
missForest compares favorably against a number of alternative imputation technique, which was the reason for 
choosing this particular method here.
imposing constraints on the network structure. Most edges in the BN structure are not known and 
hence need to be deduced from data. An important question is, in how far the learned structure then reflects 
existing causal relationships. Indeed, if the BN is faithful to the underlying statistical distribution (i.e. models 
it correctly), then the true causal network is known to be part of a class of equivalent graph structures, called 
class partially directed acyclic graph (CPDAG)10,27. Under the above mentioned assumptions, the CPDAG has the 
same skeleton as the true causal graph, but may leave some edges undirected. Hence, in practical applications, 
it is important to restrict the CPDAG equivalence class as much as possible by prior knowledge to allow correct 
orientation of as many edges as possible. In our case we specifically imposed the following constraints for BN 
structures:
• Demographic and other clinical baseline features (age, gender, ethnicity) can only influence other features, 
but they are not themselves influenced.
• Medical history can depend on motor, non-motor and other clinical features.
• Imaging features can be related to each other, but they don’t influence other features.
• Clinical diagnosis in AD is dependent on cognitive assessment scores, but not vice versa
• Clinical outcome measures (e.g. UPDRS for PD) can influence imaging and—in Parkinson—they can be 
mutually correlated with assessment of non-motor symptoms.
• Biomarkers, including genomic features, can influence all features, except for clinical baseline features.
• Longitudinal features must follow the right temporal order, i.e. there are no edges pointing backwards in 
time.
• An auxiliary variable which is created on the basis of missingness of certain feature can only influence it’s 
corresponding feature and the auxiliary variable for the same feature at the next time point (see last section 
and Figure S1).
Figures S2, S3 schematically depict the set of potentially allowed edges, which we defined between variable groups 
for the PD and AD datasets used in this work.
Dimensionality reduction via modular Bns using sparse autoencoders. Learning the true 
CPDAG structure is NP  hard28, which requires to limit the space of potential networks as much as possible. This 
is of particular importance in a situation with many variables and a limited sample size, such as ours. Module 
Networks have been introduced as a way to address such a  situation29. The key idea in Module Networks is to 
group variables into modules, which share parameters. During the BN structure learning process, only edges 
between modules are learned. In our case, variable comprised e.g. imaging related features, plasma biomarkers, 
SNPs, medical history, cognition scores, etc. The exact definition of variable groups differs between datasets 
used and is shown in the Supplementary material (Tables S3, S5). The key question is, how to learn and encode 
a shared distribution for a module. In their original publication Segal et al. relied on the assumption of normally 
distributed data (such as gene expression) and employed decision trees to represent  modules29. In this work we 
used sparse autoencoders, which can weigh the influence of different variables on to the aggregate module score. 
Furthermore, autoencoders do not make any distribution assumption. Briefly, autoencoders are a form of neural 
network, which perform non-linear dimensionality  reduction30. An autoencoder takes a feature vector x ∈ ℜd 
as input and transforms/encodes it to a hidden representation x˜ ∈ ℜq via
(1)x˜ = s(Wx + b)
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where s(·) is a non-linear activation function, e.g. sigmoid, rectified linear unit. Matrix W consists of weights 
and b is a bias vector. Several encoding steps can be performed sequentially, resulting into a deep autoencoder. 
The latent representation x˜ can be decoded/mapped back via
where W′, b′ are the parameters of the decoder that are not necessarily identical to the encoder. Moreover, s′ (·) 
is a non-linear activation function, which may be different from s(·). Autoencoders are trained to minimize the 
difference between reconstructions z and original inputs x.
In our case the mean squared error (MSE) was used for that purpose. Sparsity can be enforced by introducing 
drop-out units into the input layer of the autoencoder  network31. In addition, we used an l2 penalty for all weights. 
There was a separate sparse autoencoder trained for each variable group, and several autoencoder architectures 
and activation function combinations were tested via a grid search (see details in Supplements). In particular the, 
the grid search also involved tuning of an l2 penalty and drop-out ratios of input units. Supplementary Tables S3, 
S5 show the MSE obtained for each autoencoded module.
To understand the influence of individual features on each of the autoencoder networks, we applied the 
method by Gedeon et al.17, which is based on the idea that the relative contribution of the ith input to the jth 
output of a neuron can be estimated by:
 where the sum runs over all inputs of the neuron.  Pij can be regarded as the weight of the edge i →j in the neural 
network graph. Now assume that j itself feeds into a further neuron k. Gedeon suggests to estimate the overall 
impact of i on k by:
 That means we take the product of edge weights along a path connecting i and k and sum over all alternative 
paths. The definition can directly be extended to deeper networks.
Feature influences estimated in this way can be found for all autoencoder networks in a Supplementary Excel 
file.
Data discretization. Structure learning with BNs is only computationally efficient, if all variables fol-
low a Gaussian or multinomial distribution, because then the marginal log-likelihood, integrating out model 
parameters, can be computed  analytically10. Since in our case we had highly heterogeneous data, where many 
features were clearly non-Gaussian, we decided to perform data discretization. In case of the ADNI study (see 
“ADNI” section) this was done via a supervised, decision tree based  approach32, where baseline diagnosis of 
patients (cognitively normal, mild cognitively impaired or Alzheimer’s Disease) was taken as label. In case of the 
PPMI study (see “PPMI” section) all patients had a de novo Parkinson’s Disease diagnosis. Accordingly, we here 
employed an unsupervised univariate clustering via Gaussian Mixture Models for discretization purposes. Both 
methods result into a variable number of discrete values for each feature (Tables S3, S5).
For comparison reasons we also conducted BN structure learning without any discretization while assuming 
a Gaussian distribution for each continuous variable, see details in next section.
Bn structure and parameter learning. As a consequence of the approach described previously, any 
established BN structure learning algorithm could be applied. In this work we used six different algorithms 
implemented in the R-package bnlearn33: greedy hill climbing (50 random restarts), Max-Min Hill Climbing 
(MMHC)34, tabu  search35, Max-Min Parent Child (MMPC)34, 2-phase Restricted Maximization (RSMAX2)34 
and semi-interleaved Hiton Parent Child (SI-HITON-PC)36. Greedy hill climbing and tabu search are heuris-
tic score based optimization approaches, whereas MMPC and SI-HITON-PC are constrained-based structure 
learning methods that try to identify the Markov Blanket of each node in the Bayesian Network. MMHC and 
RSMAX2 are hybrid approaches, which use ideas from both, search-and-score as well as constrained-based tech-
niques: MMHC first learns the skeleton of the BN using the MMPC constrained-based algorithm. In a second 
phase edges are then oriented via a greedy hill climbing search. RSMAX2 uses for the first step the SI-HITON-
PC algorithm instead of MMPC.
Selection between different BN structure learning algorithms can be done via k-fold cross-validation akin 
to conventional supervised  learning10. That means the overall data is randomly split into k (here: k = 10) folds, 
and the BN structure together with its parameters successively learned from k − 1 folds. If the fitted BN correctly 
models the overall population (and not just the training data), the data in the left out fold should with high prob-
ability fall into the same statistical distribution that is described by the BN. This can be quantified via the negated 
expected log-likelihood of the test data. Accordingly, cross-validation can be used to assess the generalization 
ability of a BN model and to compare different structure learning algorithms on that basis.
In this work tabu search was identified as best performing BN structure learning algorithm for ADNI and hill 
climbing for PPMI for discretized data (Figures S4, S5). This is in agreement with recent findings that in most 
situations score based search methods are superior to constrained-based  ones37 Given a learned BN topology, 
parameters can then be inferred using a Dirichlet prior to account for parent-child node configurations that are 
not  observed38. BN structure and parameter learning was executed via the R-package  bnlearn33.
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When omitting data discretization, we end up in a BN with a mixture of Gaussian and discrete nodes (hybrid 
BN). To allow for a direct comparison with BN structure learning after discretization we used the same structure 
learning algorithm, namely tabu search. In addition, score based search algorithms have empirically found to 
show a more robust behavior in terms of network reconstruction accuracy than constraint based methods for 
mixed discrete/continuous data, specifically for smaller sample  sizes39.
Simulation of virtual patients. Given a BN with learned parameters, a virtual patient can be simulated 
by first drawing random values from parent node distributions and subsequently from their child node dis-
tributions while conditioning on the values of the parents. Each virtual patient thus corresponds to a vector 
of features, which follow the conditional statistical dependencies learned by the BN. If the BN is learned from 
discretized data, then also each virtual patient’s feature vector is discrete.
A general concern at this point is that virtual patients could show differences to real patients either due to 
insufficient model fit or due to the existence of confounding factors that are not part of the observed data, result-
ing into biases in BN parameter estimates. To account for this aspect we developed a scoring scheme, which could 
help to exclude unrealistic virtual patients directly after simulation. This was done by training a RF  classifier13, 
which puts 100 times more weight on correctly classifying original patients than simulated ones. The weighted RF 
classifier assigns to each virtual subject a probability/confidence score to fall into the real patient distribution. In 
this way we here excluded simulated patients that showed a lower than 50% probability to fall into the real patient 
distribution and could thus be regarded as outlying. The whole procedure of simulating patients and excluding 
seemingly unrealistic ones can be run iteratively until a desired number virtual patients has been generated.
Simulation of counterfactual interventions in Bayesian networks. Judea Pearl developed a well-
established theory for modeling and simulating interventions into  BNs20: Assume we want to predict the inter-
vention effect of Xk= x on the remaining random variabes in the BN, i.e. P(X1, …, Xk−1, Xk+1,..., Xn | do(Xk = x)). 
Pearl demonstrated in his work that this intervention effect can be computed by estimating the conditional 
probability distribution P(X1,..., Xk−1, Xk+1,..., Xn | Xk = x) within a multilated BN, in which all incoming edges 
into Xk have been deleted.
In practice we used logic  sampling40 for estimating the conditional probability distribution P(X1,..., Xk−1, Xk+1, 
..., Xn | Xk = x) in the multilated BN.
calculation of cortical brain region volumes. All available MR scans (T1-weighted scans) from the 
ADNI database were quantified by an open-source, automated segmentation pipeline at the Erasmus University 
Medical Center, The Netherlands. The number of slices of the T1w scans varied from 160 to 196 and the in-
plane resolution was 256 × 256 on average, yielding an overall voxel-size of 1.2 × 1.0 × 1.0 mm. From the 1715 
baseline ADNI scans, the volumes of 34 bilateral cortical brain regions, 68 structures in total, were calculated 
using a model- and surface-based automated image segmentation procedure, incorporated in the FreeSurfer 
Package (v.6.0, https ://surfe r.nmr.mgh.harva rd.edu/). Segmentation in Freesurfer was performed by rigid-body 
registration and nonlinear normalization of images to a probabilistic brain atlas. In the segmentation process, 
each voxel of the MRI volumes was labeled automatically as a corresponding brain region based on a cortex 
parcellation (subdivision) guide. In this case the cortical parcellation method, implemented by Desikan and 
Killiany in  200641, was used for brain segmentation. For the subdivision of the human cerebral cortex into gyral-
based regions, Desikan and Killiany manually identified the 34 cortical regions in the individual hemispheres. 
This information was encoded into an atlas that was utilized to automatically label ROIs. Desikan and Killiany 
showed that compared to manual segmentation there automated method reached an intra-class correlation coef-
ficient (ICC) of 0.835 across all of the ROIs. The mean distance error was less than 1 mm.
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